“This is a transformative time at Eloxx. With today’s confirmation of the disease modifying potential of ELX-02 in all three patient biopsies from the Alport syndrome trial, we look forward to advancing to a pivotal trial of ELX-02 for the treatment of Alport syndrome,” said Sumit Aggarwal, President and Chief Executive Officer of Eloxx. “We also plan to initiate a clinical study for our lead TURBO-ZM(TM) based molecule, ZKN-013, for the potential treatment of recessive dystrophic epidermolysis bullosa with first patient dosing expected by the end of 2023.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ELOX:
- Eloxx Pharma (NASDAQ:ELOX) Rises on Promising Phase 2 Data in Alport Syndrome
- Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
- Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
- Eloxx Pharmaceuticals granted extension by Nasdaq to regain compliance
- Eloxx Pharmaceuticals price target raised to $55 from $50 at Oppenheimer
